BioNTech Results Presentation Deck

BNT162 Commercial update ● ● 23 Both BioN Tech and Pfizer jointly scaling up manufacturing capacity to enable global supply: ▪ BioN Tech already producing vaccine for clinical supply at 2 manufacturing sites in Germany ▪ Pfizer will activate 3 manufacturing sites in the U.S. and 1 site in Europe Joint BioN Tech and Pfizer capacity targets for 2020 and 2021: ■ ■ Up 100 million doses by the end of 2020 Approximately 1.3 billion doses by the end of 2021 BioNTech and Fosun working separately to build up manufacturing capacity for China market Commercial supply contracts signed to-date # of doses 30 million Region United Kingdom United States Japan Canada 100 million with option for additional 500 million 120 million Not disclosed Contract value Not disclosed $1.95 billion for first 100 million doses Not disclosed Not disclosed >250m doses contracted for 2020 and 2021 subject to clinical success and regulatory approval Commercial discussions ongoing with additional governments around the world BIONTECH

View entire presentation